Haloperidol, marketed as Haldol, has been on the market since 1967. It was the medication that defined the modern era of antipsychotic treatment, and for decades it was the standard against which everything else was measured. Today, it has been largely replaced by atypical antipsychotics for routine use — for good reason, because its movement-related side effects are significant. But it has not disappeared, and there are specific situations in which it remains the right choice. Understanding both why we use it less than we used to and why we still use it at all is the right starting point.
Haloperidol is a potent, inexpensive, and reliable D2 antagonist with significant rates of EPS and tardive dyskinesia — replaced for routine use by atypicals but still useful in acute agitation, treatment failures, and resource-limited settings.
Where the side effects come from
Haloperidol is a high-potency dopamine D2 receptor antagonist. It binds tightly and selectively, with relatively little activity at histamine, muscarinic, or alpha-adrenergic receptors. This is the opposite of clozapine or quetiapine, which are "broad-spectrum" antipsychotics. The narrow targeting has consequences: less sedation and less weight gain than many atypicals, but unmodulated D2 blockade in motor pathways — which is what produces extrapyramidal symptoms (EPS).
Extrapyramidal symptoms (EPS)
EPS is the defining side-effect category for haloperidol. The four main forms:
- Acute dystonia — sudden, sustained muscle contractions, particularly of the neck (torticollis), eyes (oculogyric crisis), tongue, or jaw. Often appears within hours to days of starting or after dose increases. Particularly common in young men, in higher doses, and with high-potency typicals like haloperidol.
- Akathisia — inner restlessness and inability to sit still. One of the most common reasons patients refuse to continue haloperidol.
- Drug-induced parkinsonism — tremor, stiffness, slowed movement, masked facial expression, shuffling gait. Often dose-dependent.
- Tardive dyskinesia — involuntary movements, particularly of the face, lips, tongue, and sometimes limbs. Usually appears after months to years of treatment. Can be permanent even after the medication is stopped.
For broader detail see our EPS overview and tardive dyskinesia explainer.
Sudden severe muscle contractions of the neck, eyes, jaw, or tongue need prompt evaluation. They are typically reversed within minutes by intramuscular benztropine or diphenhydramine but can be frightening and, rarely, dangerous if airway muscles are involved.
Mitigation strategies for EPS
- Lower doses where possible
- Anticholinergic medications (benztropine, trihexyphenidyl) for parkinsonism and dystonia
- Beta-blockers (propranolol) for akathisia
- VMAT2 inhibitors (valbenazine, deutetrabenazine) for tardive dyskinesia
- Switching to a lower-EPS atypical when persistent
Tardive dyskinesia: the long-term concern
Tardive dyskinesia (TD) rates with haloperidol are substantial — the cumulative incidence is approximately 5% per year of exposure in adults, higher in older adults. After 5 years, around 25% of patients on continuous haloperidol may develop some degree of TD. This is one of the most important reasons modern guidelines favour atypical antipsychotics for long-term maintenance treatment when feasible.
That said, atypicals are not free of TD risk — just lower. And for patients who require long-term haloperidol because of treatment failures or other constraints, the ongoing risk requires regular AIMS (Abnormal Involuntary Movement Scale) screening — typically every six months.
Neuroleptic malignant syndrome (NMS)
NMS is a rare (under 1%) but life-threatening reaction characterised by high fever, severe muscle rigidity, autonomic instability (blood pressure swings, sweating, rapid heart rate), and altered consciousness. Haloperidol, particularly at higher doses or rapid escalation, is among the antipsychotics most associated with NMS in case series. It is a medical emergency.
Cardiac effects
Intravenous haloperidol can cause significant QT prolongation and has been associated with rare cases of torsades de pointes — a dangerous arrhythmia. The FDA has a specific warning about this risk, particularly with IV use, which is not an FDA-approved route. Oral and intramuscular haloperidol carry less risk but are still relevant for patients with cardiac disease or on other QT-prolonging medications. See QT prolongation.
Prolactin
Haloperidol substantially elevates prolactin, with effects similar to or greater than risperidone. Symptoms can include menstrual irregularities, galactorrhea, sexual dysfunction, and long-term concerns about bone density. See hyperprolactinemia and antipsychotics.
Sedation and metabolic effects: relatively favourable
Haloperidol is less sedating than olanzapine or quetiapine, and produces less weight gain than most atypicals. Its metabolic profile is generally favourable — lighter than clozapine, olanzapine, and risperidone. This is one of the underappreciated reasons it sometimes makes sense in patients with significant metabolic concerns where movement risk can be carefully managed.
Why haloperidol is still used
- Acute agitation — IM haloperidol, often combined with lorazepam, is one of the most effective rapid tranquillisers in emergency settings
- Long-acting injectable maintenance — haloperidol decanoate is a monthly LAI used widely in resource-constrained settings
- Treatment failures — some patients respond to haloperidol when atypicals haven't worked
- Cost — generic haloperidol is among the cheapest antipsychotics globally, central to WHO essential medicines lists
- Pregnancy — long safety record makes it a relatively common choice when antipsychotic treatment is needed during pregnancy
Boxed warnings
- Increased mortality in elderly patients with dementia-related psychosis (class-wide)
- Risk of QT prolongation and arrhythmia, particularly with IV use (which is not an FDA-approved route)
When to call the prescriber
- Restlessness or inability to sit still
- New tremor or stiffness
- Sustained muscle contractions of the neck, eyes, or jaw — this is an urgent issue
- Involuntary movements of the mouth, tongue, or face
- Sexual side effects, menstrual changes, or breast changes
- High fever with muscle rigidity and confusion — emergency
Switching considerations
For patients who can tolerate haloperidol's efficacy but not its side effects, common alternatives include:
- Risperidone or paliperidone — atypicals with similar D2 potency and slightly lower EPS
- Aripiprazole — partial agonist with much lower EPS
- Olanzapine — broader receptor profile, much lower EPS but heavier metabolic burden
- For long-acting injectable continuity: aripiprazole monohydrate, aripiprazole lauroxil, paliperidone palmitate
The bigger context
Haloperidol's reputation has shifted from "first-line standard" to "still useful in specific contexts." For a patient and family being offered it today, the right framing is usually: this is a powerful, reliable, well-understood medication whose movement-related risks need active monitoring. It is not the modern default — but it is also not obsolete. The conversation worth having with a prescriber is why this drug, in this situation, makes sense.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.